Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation

Table 2

Post-solid organ transplant t-MNs at the University of Chicago.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age/sex (years)	57/M	56/M	50/M	58/F	55/F
Organ transplant	Heart	Kidney	Heart	Liver	Kidney
Immuno-suppressive therapy	CsA; MMF; Prednisone	CsA; MMF; Prednisone	CsA; azathioprine Prednisone	CsA; azathioprine Prednisone	Cytoxan; Prednisone
Latency (years)	4.3	4.4	12.3	7.7	7
WHO classification	t-AML	t-AML	t-MDS	t-MDS	t-MDS
Treatment	Induction chemo + allo-HCT	Induction chemo + allo-HCT	Induction chemo + auto-HCT	Induction chemo	Supportive care
Survival (years)	1	1.5	3.6	1.3	1.9
Karyotype	46XY, inv(9)c, t(10;11)	Normal	46XY, 55%; 46XY, del 7, 25%; 46XY, del 11, 20%	Normal	46XX, 55%; 46XX, inv(9)c, del 7, 41%; 46XX, inv(9)c, del 19, 4%